摘要

抗菌素耐药性的迅速发展要求开发新的解决方案来对抗老敌人。利用裂解噬菌体（噬菌体）治疗耐药细菌感染是近年来获得重大进展的一种方法。在实验性噬菌体治疗病例报告的推动下，美国已开展了几项噬菌体治疗产品的早期临床试验。最终的许可证使人们能够广泛接触噬菌体是目标；然而，必须首先建立新的途径来获得监管批准和大规模市场分布，这与小分子抗生素不同。这篇综述强调了与噬菌体临床应用相关的独特方面，包括需要获得的优势以及需要克服的挑战。

Burgeoning problems of antimicrobial resistance dictate that new solutions be developed to combat old foes. Use of lytic bacteriophages (phages) for the treatment of drug-resistant bacterial infections is one approach that has gained significant traction in recent years. Fueled by reports of experimental phage therapy cases with very positive patient outcomes, several early-stage clinical trials of therapeutic phage products have been launched in the United States. Eventual licensure enabling widespread access to phages is the goal; however, new paths to regulatory approval and mass-market distribution, distinct from those of small-molecule antibiotics, must be forged first. This review highlights unique aspects related to the clinical use of phages, including advantages to be reaped as well as challenges to be overcome.

https://www.ncbi.nlm.nih.gov/pubmed/31185183